Amarin aims for Vascepa boom with doubled sales force nearly in place

Amarin Vascepa pill
Amarin's Vascepa received a heart-helping FDA nod in late December. (Amarin)

Amarin scored an FDA win with blockbuster potential last year when its fish oil-derivative Vascepa received a heart-helping nod on top of statins. Now, with Amarin's fleshed out salesforce nearly in place and prescriptions soaring, the drugmaker is ready to take Vascepa to the next level. 

Amarin closed 2019 with a whopping 87% increase in revenue to $429 million, riding skyrocketing prescriptions for Vascepa, which jumped 78% on the year, the company said Wednesday. 

In a fourth-quarter earnings call with analysts, CEO John Thero said Amarin's doubled salesforce of 800 reps was nearly in place and ready to capitalize on the FDA's label expansion of Vascepa in December to include a risk reduction of cardiovascular events in patients with abnormally high triglycerides. 

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

"I think we've hired terrific people," Thero said. "We've got terrific managers, the launch materials are crisp, it's nice to be out with an FDA label, which makes the description of what we're doing much easier. I think the other promotional materials and particularly the DTC advertising, I think it's going to help lift things considerably."

RELATED: JPM: With Vascepa's U.S. expansion rolling, Amarin CEO holds off partner offers in EU 

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.